Heart Failure

ESC Congress 2023. The results of STEP-HFpEF could "change the nature of the conversation about the role of obesity in HFpEF," said PI Mikhail Kosiborod, MD.

A daily dose of clinical news on Patient Care you may have missed.

A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.

The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?

Regardless of the pattern of physical activity, it may reduce risk across a spectrum of cardiovascular diseases, say study authors. So, just do it!

Your daily dose of clinical news you may have missed.

Wellbeing is considered a measurable and modifiable community attribute that study authors show is correlated with CV outcomes.

Your daily dose of clinical news you may have missed.

SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.

Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.

Your daily dose of clinical news you may have missed.

In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.

The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.

“Patients with COPD who have AMI are less aggressively treated than those without COPD," leading to higher in-hospital mortality and long-term mortality,” wrote authors.

The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with HFmrEF or HFpEF.

Studies on supervised exercise training in patients with chronic, stable HFpEF suggest substantial improvements in exercise capacity and QoL that may surpass those seen with medication.

ACC 2023. In an analysis of patients with heart failure, never having been married was associated with worse survival compared with having been married.

Your daily dose of clinical news you may have missed.

After hospital discharge for heart failure, adults treated with either furosemide or torsemide had similar mortality rates, according to results from the TRANSFORM-HF clinical trial.

Patient Care Guideline Toplines summarize newly revised and updated clinical recommendations from professional societies for convenient, at-a-glance review.

Approved in 2020 as Nexletol, bempedoic acid as the first ATP citrate lyase inhibitor and oral non-statin therapy to meet the MACE-4 primary endpoint.

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

SGLT-2 inhibitors and drugs to treat HFrEF were compared for efficacy in patients with HF with LVEF ≥40%.

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.